Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyx144
Abstract: Objective This Phase I study (NCT01605916) investigated the safety, tolerability and pharmacokinetic profile of selumetinib plus docetaxel as second-line therapy in Japanese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), or selumetinib… read more here.
Keywords: selumetinib; combination; safety tolerability; japanese patients ... See more keywords